SYRE: Spyre Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Historical context for SYRE
Across the 24 sessions after earlier SYRE headlines, the stock closed higher 19 times and lower 5 times, with a median move of 2.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | SYRE | SPY |
|---|---|---|---|
| May 27, 2026 | Spyre Therapeutics to Participate in Upcoming June Investor Conferences | -1.5% | -0.0% |
| May 5, 2026 | Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | +2.7% | +0.8% |
| May 4, 2026 | Spyre Therapeutics Announces Grants of Inducement Awards | -0.4% | -0.4% |
| Apr 17, 2026 | Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million | +4.7% | +1.2% |
| Apr 15, 2026 | Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock | +7.8% | +0.8% |
| Apr 14, 2026 | Raymond James initiated coverage on Spyre Therapeutics with a new price targetand 1 other headline that session | +1.2% | +1.2% |
Quantisnow market dataNASDAQ
SYRE
Spyre Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2016
Get push alerts for SYRE
Full SYRE profile on Quantisnow Follow SYRE and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time